Non-Small Cell Lung Cancer (NSCLC) | Topics

New 5-Year KEYNOTE-024 Data Show Pembrolizumab Continues to Prolong OS in NSCLC
May 11, 2021

Patients with non–small cell lung cancer and PD-L1 tumor proportion scores of at least 50% had a median 5-year overall survival rate of 26.3%, showing a significant improvement versus standard of care.

Tremelimumab and Durvalumab Combo for Stage IV NSCLC Reaches Significance for OS
May 07, 2021

Data reported from the phase 3 POSEIDON trial are the first to demonstrate a statically significant overall survival benefit with tremelimumab.

FDA Grants Priority Review to Mobocertinib for EGFR Exon 20 Insertion+ Metastatic NSCLC
April 28, 2021

Based on response efficacy in a phase 1/2 trial, the FDA granted the selective oral tyrosine kinase inhibitor mobocertinib priority review for patients with pretreated metastatic non–small cell lung cancer harboring insertion mutations in EGFR exon 20.